Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7379MR)

This product GTTS-WQ7379MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL), Chronic lymphocytic leukemia (CLL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7379MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6122MR IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA COR-001
GTTS-WQ8332MR IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HN-66000
GTTS-WQ5190MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CAT-354
GTTS-WQ14554MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SAR156597
GTTS-WQ8650MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ11444MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI-9447
GTTS-WQ8950MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ2622MR IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG 557
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW